{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:23:00Z","timestamp":1793107380999,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["321990\/Z\/24\/Z"],"award-info":[{"award-number":["321990\/Z\/24\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X00094X\/1"],"award-info":[{"award-number":["MR\/X00094X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:46:37Z","timestamp":1770381997000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current drug hypersensitivity challenges facing patients with cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-108X","authenticated-orcid":false,"given":"Joshua","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-0606","authenticated-orcid":false,"given":"Elsie","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-8852","authenticated-orcid":false,"given":"Jobst F.","family":"Roehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Naisbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112844","article-title":"CFTR protein: not just a chloride channel?","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0003","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0005","doi-asserted-by":"crossref","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Research"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cystic Fibrosis"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.010_bib0007","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.01.010_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14113978","article-title":"Cystic Fibrosis transmembrane conductance regulator modulators in Cystic Fibrosis: a review of registry-based evidence","volume":"14","author":"Salvatore","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0011","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/ACI.0b013e328355b849","article-title":"Nonimmediate \u03b2-lactam reactions in patients with cystic fibrosis","volume":"12","author":"Whitaker","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jcf.2026.01.010_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124335","article-title":"Reported adverse events in patients with CF receiving treatment with Elexacaftor\/Tezacaftor\/Ivacaftor: 5 years observational study","volume":"14","author":"Lucca","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0013","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcf.2006.11.001","article-title":"Beta-lactam allergy in adults with cystic fibrosis","volume":"6","author":"Burrows","year":"2007","journal-title":"J Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0014","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: a mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2026.01.010_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1392986","article-title":"Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor\/tezacaftor\/ivacaftor","volume":"15","author":"G\u00f3mez-Ganda","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0016","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4(+) T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13815","article-title":"T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis","volume":"33","author":"Semic-Jusufagic","year":"2022","journal-title":"Pediatric Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0018","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.01.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.03.003","article-title":"Immunogenic adverse events to CFTR modulators \u2013 an international survey","author":"Urbantat","year":"2025","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.01.010_bib0020","series-title":"Annual data report to the center directors","article-title":"Patient registry 2021","author":"Foundation","year":"2021"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00282-2024","article-title":"Isolation of Burkholderia cepacia complex in adults with primary ciliary dyskinesia","volume":"10","author":"Spoletini","year":"2024","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0023","first-page":"239","article-title":"Tobramycin and beta-lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach","volume":"21","author":"Zobell","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0024","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/thx.2004.027953","article-title":"Antibiotic allergy in cystic fibrosis","volume":"60","author":"Parmar","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1440-1754.1998.00197.x","article-title":"Antibiotic hypersensitivity reactions in cystic fibrosis","volume":"34","author":"WILLS","year":"1998","journal-title":"J Paediatr Child Health"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0026","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/ppul.26073","article-title":"Antibiotic allergy in children with cystic fibrosis: a retrospective case-control study","volume":"57","author":"S\u00fcleyman","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0027","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2125.2010.03703.x","article-title":"Skin manifestations of drug allergy","volume":"71","author":"Ardern-Jones","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0028","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jcf.2026.01.010_bib0029","doi-asserted-by":"crossref","first-page":"S608","DOI":"10.1093\/clinids\/13.Supplement_7.S608","article-title":"Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses","volume":"13 Suppl 7","author":"Koch","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/CRIAI:24:3:201","article-title":"Hypersensitivity reactions to beta-lactam antibiotics","volume":"24","author":"Solensky","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0031","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2013.10.002","article-title":"Hypersensitivity to antibiotics in patients with cystic fibrosis","volume":"13","author":"Roehmel","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0032","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1111\/bcp.15434","article-title":"Antibiotic hypersensitivity in cystic fibrosis \u2013 Low frequency of anaphylaxis over 16\u2009000 courses","volume":"88","author":"Kowalik","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0033","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/jpet.111.190900","article-title":"Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis","volume":"341","author":"El-Ghaiesh","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0034","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.4049\/jimmunol.1700209","article-title":"Definition of the nature and hapten threshold of the beta-lactam antigen required for T cell activation In","volume":"198","author":"Meng","year":"2017","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.1100647","article-title":"Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis","volume":"187","author":"Whitaker","year":"2011","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0036","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/tx400124m","article-title":"beta-lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis","volume":"26","author":"Jenkins","year":"2013","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.010_bib0037","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ni.1770","article-title":"Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells","volume":"10","author":"Trifari","year":"2009","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.01.020","article-title":"beta-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0039","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1021\/acs.chemrestox.2c00231","article-title":"Shared clavulanate and tazobactam antigenic determinants activate T-cells from hypersensitive patients","volume":"35","author":"Ariza","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0040","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.jaip.2020.12.051","article-title":"Piperacillin-tazobactam hypersensitivity: a large, multicenter analysis","volume":"9","author":"Casimir-Brown","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0041","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","article-title":"An update on CFTR modulators as new therapies for cystic fibrosis","volume":"24","author":"King","year":"2022","journal-title":"Pediatric Drugs"},{"key":"10.1016\/j.jcf.2026.01.010_bib0042","unstructured":"Agency E.M. Kalydeco 2024 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kalydeco."},{"key":"10.1016\/j.jcf.2026.01.010_bib0043","unstructured":"Agency E.M. Orkambi 2023 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orkambi."},{"key":"10.1016\/j.jcf.2026.01.010_bib0044","unstructured":"Agency E.M. Kaftrio 2024 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio."},{"key":"10.1016\/j.jcf.2026.01.010_bib0045","unstructured":"EM A. Alyfrek 2025 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alyftrek."},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2026.01.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108180","article-title":"In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G\/A234D) in primary human rectal and nasal epithelial cells","volume":"26","author":"Kleinfelder","year":"2023","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.jcf.2026.01.010_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210358","article-title":"Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to elexacaftor (VX-445) and tezacaftor (VX-661) combination","volume":"24","author":"Kleinfelder","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0049","first-page":"192","article-title":"The first triple-combination Cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatric Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cystic Fibrosis"},{"issue":"19","key":"10.1016\/j.jcf.2026.01.010_bib0051","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.01.010_bib0052","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del Allele: a phase 3, open-label extension study","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.01.010_bib0053","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0054","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0056","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0057","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17476348.2019.1602040","article-title":"Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis","volume":"13","author":"Cheng","year":"2019","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0058","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies","year":"2021","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0059","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0061","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.01.010_bib0062","unstructured":"Foundation. CF. Patient Registry Highlights 2024 [Available from: https:\/\/www.cff.org\/medical-professionals\/2024-patient-registry-highlights."},{"key":"10.1016\/j.jcf.2026.01.010_bib0063","article-title":"Wellness in the modulator era: an observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","author":"Van Citters","year":"2024","journal-title":"J Cystic Fibrosis"},{"issue":"12","key":"10.1016\/j.jcf.2026.01.010_bib0064","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0065","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0066","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.010_bib0067","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2011.02.024","article-title":"Drug induced liver injury and its relationship to autoimmune hepatitis","volume":"55","author":"Weiler Normann","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0068","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOG.0000000000000432","article-title":"Liver disease in patients with cystic fibrosis","volume":"34","author":"Kamal","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0069","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.010_bib0070","unstructured":"Naimimohasses S., Ray A., Tan E., Wiggins A., Hasjim B.J., Chen S., et al. Impact of cystic fibrosis transmembrane conductance regulator modulating therapies on liver transplant outcomes. Gastro Hep Advances."},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0071","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation","volume":"15","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"9","key":"10.1016\/j.jcf.2026.01.010_bib0073","article-title":"Malassezia folliculitis following triple therapy for Cystic fibrosis","volume":"58","author":"Li Pomi","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0074","first-page":"463","article-title":"Rechallenge of elexacaftor\/tezacaftor\/ivacaftor after skin rash in two pediatric patients","volume":"27","author":"Diseroad","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0075","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of Elexacaftor-Tezacaftor-ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0076","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.01.010_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1107437","article-title":"Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"14","author":"Westh\u00f6lter","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcf.2026.01.010_bib0078","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coi.2015.01.012","article-title":"The role of T cell receptor signaling thresholds in guiding T cell fate decisions","volume":"33","author":"Zikherman","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/1535370217733425","article-title":"Biomarkers of adverse drug reactions","volume":"243","author":"Carr","year":"2018","journal-title":"Exp Biol Med (Maywood, NJ)"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.103.050112","article-title":"Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans","volume":"306","author":"Farrell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0081","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0082","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1021\/acs.chemrestox.1c00425","article-title":"Characterization of teicoplanin-specific T-cells from drug na\u00efve donors expressing HLA-A*32:01","volume":"35","author":"Gardner","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0083","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/mol.63.3.732","article-title":"Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones","volume":"63","author":"Naisbitt","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jcf.2026.01.010_bib0084","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfaf074","article-title":"Elucidating CD4+ and CD8+ T-cell involvement in patients with vancomycin-induced DRESS","author":"Gardner","year":"2025","journal-title":"Toxicol Sci"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.010_bib0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0086","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/1547691X.2016.1254305","article-title":"Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response","volume":"14","author":"Whritenour","year":"2017","journal-title":"J Immunotoxicol"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0087","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cea.13076","article-title":"Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment","volume":"48","author":"Caba\u00f1as","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jcf.2026.01.010_bib0088","article-title":"Phenotypic and functional characterisation of liver-infiltrating T-cells in a case of CFTR modulator induced drug-induced liver injury","author":"Clarke","year":"2025","journal-title":"J Cystic Fibrosis"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0089","doi-asserted-by":"crossref","first-page":"211","DOI":"10.18176\/jiaci.0961","article-title":"Protocol for successful desensitization to Ivacaftor and Elexacaftor\/Tezacaftor\/Ivacaftor in a delayed hypersensitivity reaction confirmed by the lymphocyte transformation test","volume":"34","author":"Mir-Ihara","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jcf.2026.01.010_bib0090","article-title":"Prospective piperacillin lymphocyte transformation testing in patients with cystic fibrosis receiving regular and desensitization courses of piperacillin-tazobactam","author":"Whitaker","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3 Supplement","key":"10.1016\/j.jcf.2026.01.010_bib0091","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jcf.2026.01.010_bib0092","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.4049\/jimmunol.2100424","article-title":"Mucosal immunity in cystic fibrosis","volume":"207","author":"Bojanowski","year":"2021","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0093","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041952","article-title":"Dysfunctional inflammation in Cystic Fibrosis airways: from mechanisms to novel therapeutic approaches","volume":"22","author":"Ghigo","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0094","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcf.2004.06.006","article-title":"Cytokines and inflammatory mediators in cystic fibrosis","volume":"3","author":"Courtney","year":"2004","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.01.010_bib0095","article-title":"Feedback regulation of VISTA and Treg by TNF-\u03b1 controls T cell responses in drug allergy","author":"Sun","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0096","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.01.010_bib0097","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0098","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcf.2016.05.016","article-title":"Airway inflammation in mild cystic fibrosis","volume":"16","author":"Eckrich","year":"2017","journal-title":"J Cystic Fibrosis"},{"issue":"2","key":"10.1016\/j.jcf.2026.01.010_bib0099","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/thx.46.2.91","article-title":"Plasma tumour necrosis factor alpha in cystic fibrosis","volume":"46","author":"Norman","year":"1991","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jcf.2009.08.002","article-title":"A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity","volume":"8","author":"Legere","year":"2009","journal-title":"J Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0101","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1081-1206(10)61778-4","article-title":"Antibiotic desensitization for the allergic patient: 5 years of experience and practice","volume":"92","author":"Turvey","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.jcf.2026.01.010_bib0102","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2011.02.002","article-title":"Rapid desensitization for non-immediate reactions in patients with cystic fibrosis","volume":"10","author":"Whitaker","year":"2011","journal-title":"J Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0103","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.4049\/jimmunol.1100374","article-title":"Foxp3+ regulatory T cells impede the priming of protective CD8+ T cells","volume":"187","author":"Ertelt","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0104","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1038\/s41467-024-51138-7","article-title":"Covalent penicillin-protein conjugates elicit anti-drug antibodies that are clonally and functionally restricted","volume":"15","author":"Deimel","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcf.2023.12.003","article-title":"Lymphocyte transformation tests predict delayed-type allergy to piperacillin\/tazobactam in patients with cystic fibrosis","volume":"23","author":"Roehmel","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2026.01.010_bib0106","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.jcf.2026.01.010_bib0107","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ppul.25938","article-title":"At-home compounding preparation of slow desensitization of elexacaftor\/tezacaftor\/ivacaftor for delayed hypersensitivity rash","volume":"57","author":"Muirhead","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2026.01.010_bib0108","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ppul.24319","article-title":"Ivacaftor drug desensitization","volume":"54","author":"Patterson","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2026.01.010_bib0109","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jcf.2023.03.015","article-title":"Drug desensitization to lumacaftor\/ivacaftor: a fast lane to drug tolerance","volume":"22","author":"Westhoff","year":"2023","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.jcf.2026.01.010_bib0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.anai.2021.08.010","article-title":"Elexacaftor\/tezacaftor\/ivacaftor outpatient desensitization","volume":"128","author":"Balijepally","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jcf.2026.01.010_bib0111","unstructured":"Vertex Announces US FDA Approval of ALYFTREK\u2122, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis [press release]. 20.12.2024 2024."},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0112","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/acs.jmedchem.4c02547","article-title":"Discovery and development of CFTR modulators for the treatment of cystic fibrosis","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jcf.2026.01.010_bib0113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:31:01Z","timestamp":1785411061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000299"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current drug hypersensitivity challenges facing patients with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}